TELA Bio to Announce Fourth Quarter and Full Year 2025 Financial Results
Rhea-AI Summary
TELA Bio (NASDAQ: TELA) will report fourth quarter and full year 2025 financial results on Tuesday, March 24, 2026.
Management will host a conference call and webcast at 4:30 p.m. ET to discuss results and provide a corporate update. Investors must register at least one day ahead or 15 minutes before the call. A live webcast and replay will be available on TELA's investor Events & Presentations page.
Positive
- None.
Negative
- None.
News Market Reaction – TELA
In the Mar 11 session, TELA declined 7.35%, reflecting a notable negative market reaction. Argus tracked a trough of -7.8% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 20 | Inducement grants | Neutral | +6.8% | RSU inducement grants for new hires under Nasdaq Rule 5635(c)(4). |
| Jan 23 | Inducement grants | Neutral | -1.0% | Restricted stock unit grants to five newly hired employees. |
| Dec 12 | Inducement grants | Neutral | -1.7% | RSU inducement grants totaling 3,600 shares to new employees. |
| Nov 19 | Conference participation | Neutral | -8.5% | Participation in Piper Sandler 37th Annual Healthcare Conference. |
| Nov 17 | Inducement grants | Neutral | +3.5% | Equity awards including 30,200 RSUs and a 25,000-share option grant. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent routine corporate and inducement grant announcements have typically produced modest single‑digit price moves, with both positive and negative reactions.
Over the past several months, TELA Bio has mainly issued routine updates, including multiple inducement grant announcements in November 2025, December 2025, January 2026, and February 2026, plus participation in a major healthcare conference on December 3, 2025. These items led to generally modest one‑day moves, ranging from declines of 8.47% to gains of 6.77%. Today’s earnings date notice fits within this pattern of operational and corporate housekeeping news.
Key Terms
soft-tissue reconstruction medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report fourth quarter and full year 2025 financial results on Tuesday, March 24, 2026. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
Fourth Quarter Earnings Conference Call and Webcast Details
Investors interested in listening to the conference call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the start of the call. A live webcast and replay can be accessed via the Events & Presentations page of the investor section of TELA's website.
About TELA Bio, Inc.
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. For more information, visit www.telabio.com.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA Bio's management. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements. These risks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact
Louisa Smith
ir@telabio.com
